Luteolin Inhibits NLRP3 Inflammasome Activation to Ameliorate DSS-Induced Colitis by Regulating AMPK Signalling

References

[1] T. Kobayashi, B. Siegmund, C. Le Berre, et al., “Ulcerative Colitis,” Nature Reviews Disease Primers 6, no. 1 (2020): 74.

[2] Z. Chen, G. Huang, G. Fang, et al., “Nobiletin Regulates Gut Microbiota and Mediates HIF-1α to Alleviate DSS-Induced Ulcerative Colitis by Inhibiting Ferroptosis,” Journal of Agricultural and Food Chemistry 73, no. 31 (2025): 19427–19441.

[3] S. C. Ng, H. Y. Shi, N. Hamidi, et al., “Worldwide Incidence and Prevalence of Inflammatory Bowel Disease in the 21st Century: A Systematic Review of Population-Based Studies,” Lancet (London, England) 390, no. 10114 (2017): 2769–2778.

[4] Y. Sun, G. Fang, K. Liu, et al., “Natural Polyphenol Rutin Inhibits Ferroptosis in Ulcerative Colitis by Regulating Lipid Metabolism via Blocking the LCN2-ALOX15 Axis,” Food & Function 16 (2025): 7169–7186.

[5] K. O. Chudy-Onwugaje, K. E. Christian, F. A. Farraye, and R. K. Cross, “A State-of-the-Art Review of New and Emerging Therapies for the Treatment of IBD,” Inflammatory Bowel Diseases 25, no. 5 (2019): 820–830.

[6] L. E. Targownik and C. N. Bernstein, “Infectious and Malignant Complications of TNF Inhibitor Therapy in IBD,” American Journal of Gastroenterology 108, no. 12 (2013): 1835–1842, quiz 1843.

[7] T. Strowig, J. Henao-Mejia, E. Elinav, and R. Flavell, “Inflammasomes in Health and Disease,” Nature 481, no. 7381 (2012): 278–286.

[8] K. Schroder and J. Tschopp, “The Inflammasomes,” Cell 140, no. 6 (2010): 821–832.

[9] H. H. Shen, Y. X. Yang, X. Meng, et al., “NLRP3: A Promising Therapeutic Target for Autoimmune Diseases,” Autoimmunity Reviews 17, no. 7 (2018): 694–702.

[10] M. Imran, A. Rauf, T. Abu-Izneid, et al., “Luteolin, a Flavonoid, as an Anticancer Agent: A Review,” Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie 112 (2019): 108612.

[11] S. Wang, M. Cao, S. Xu, et al., “Luteolin Alters Macrophage Polarization to Inhibit Inflammation,” Inflammation 43, no. 1 (2020): 95–108.

[12] T. J. Lin, S. Y. Yin, P. W. Hsiao, N. S. Yang, and I. J. Wang, “Transcriptomic Analysis Reveals a Controlling Mechanism for NLRP3 and IL-17A in Dextran Sulfate Sodium (DSS)-Induced Colitis,” Scientific Reports 8, no. 1 (2018): 14927.

[13] H. X. Guo, Z. H. Ji, B. B. Wang, et al., “Luteolin Modulate Endoplasmic Reticulum Stress by Targeting SIRT1 to Ameliorate DSS-Induced Ulcerative Colitis in Mice,” FASEB Journal 39, no. 7 (2025): e70529.

[14] S. Yang, H. Duan, J. Zeng, et al., “Luteolin Modulates Macrophage Phenotypic Switching via the AMPK-PPARγ Pathway to Alleviate Ulcerative Colitis in Mice,” Journal of Ethnopharmacology 339 (2025): 119157.

[15] O. Gross, C. J. Thomas, G. Guarda, and J. Tschopp, “The Inflammasome: An Integrated View,” Immunological Reviews 243, no. 1 (2011): 136–151.

[16] K. V. Swanson, M. Deng, and J. P. Ting, “The NLRP3 Inflammasome: Molecular Activation and Regulation to Therapeutics,” Nature Reviews Immunology 19, no. 8 (2019): 477–489.

[17] Y. Yang, H. Wang, M. Kouadir, H. Song, and F. Shi, “Recent Advances in the Mechanisms of NLRP3 Inflammasome Activation and Its Inhibitors,” Cell Death & Disease 10, no. 2 (2019): 128.

[18] M. Y. Chen, X. J. Ye, X. H. He, and D. Y. Ouyang, “The Signaling Pathways Regulating NLRP3 Inflammasome Activation,” Inflammation 44, no. 4 (2021): 1229–1245.

[19] W. C. Chou, E. Rampanelli, X. Li, and J. P. Ting, “Impact of Intracellular Innate Immune Receptors on Immunometabolism,” Cellular and Molecular immunology 19, no. 3 (2022): 337–351.

RIGHTS & PERMISSIONS

2025 The Author(s). Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.